enGene (NASDAQ:ENGN) Stock Rating Lowered by UBS Group

enGene (NASDAQ:ENGN) was downgraded by research analysts at UBS Group from a “buy” rating to a “neutral” rating in a research report issued on Friday, Marketbeat reports. They presently have a $7.00 price target on the stock, down from their prior price target of $34.00. UBS Group’s price objective indicates a potential upside of 18.64% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Citizens Jmp raised enGene to a “strong-buy” rating in a research note on Monday, November 18th. Raymond James began coverage on enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target on the stock. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of enGene in a research note on Monday, December 23rd. Finally, HC Wainwright began coverage on enGene in a research note on Monday, December 23rd. They set a “buy” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, enGene currently has a consensus rating of “Buy” and a consensus target price of $26.44.

enGene Price Performance

ENGN stock opened at $5.90 on Friday. enGene has a 1 year low of $4.42 and a 1 year high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The stock’s 50 day moving average price is $6.87 and its 200 day moving average price is $7.28. The firm has a market cap of $260.87 million, a P/E ratio of -10.17 and a beta of -0.65.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. On average, sell-side analysts expect that enGene will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Blue Owl Capital Holdings LP raised its position in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after buying an additional 101,006 shares during the period. Franklin Resources Inc. raised its position in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after purchasing an additional 389,918 shares during the period. Point72 Asset Management L.P. raised its position in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after purchasing an additional 619,100 shares during the period. Jane Street Group LLC purchased a new position in enGene in the fourth quarter valued at about $93,000. Finally, Vontobel Holding Ltd. purchased a new position in enGene in the fourth quarter valued at about $69,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.